



World Organization for Specialized Studies  
on Diseases of the Esophagus

## OESO Newsletter – October 2020

Message to the members of OESO,  
and to all those who have interest in Esophagology



### The OESO-SEMPIRE VIRTUAL EDUCATIONAL CHANNEL 4th meeting

**Thursday, October 29, 2020**

Hosted by **Jie He** and **Yousheng Mao**  
China National Cancer Center  
Cancer Hospital, Chinese Academy of Medical Sciences

Multidisciplinary Panels for the discussions:

China: **Zhentao Yu** (Shenzen) – **Yongtao Han** (Chengdu) – **Keneng Chen** (Beijing) –  
**Junfeng Liu** (Shijiazhuang) – **Qi Xue** (Beijing) – **Yin Li** (Beijing) – **Lijie Tan** (Shanghai) –  
**Chun Chen** (Fuzhou) – **Hecheng Li** (Shanghai) – **Xiangning Fu** (Wuhan) –  
**Zhigang Li** (Shanghai) – **Shun Xu** (Shenyang) – **Yong Li** (Beijing) –  
**Jianjun Qin** (Beijing) – **Hon Yang** (Guangzhou) – **Zhen Wang** (Beijing) –  
**Xuefeng Leng** (Chengdu) – **Jiagen Li** (Beijing)

USA: **Andrew Chang** (Ann Arbor)    Kenya: **Russell White** (Bomet)

Switzerland: **Stefan Mönig** (Geneva)    Germany: **Thorsten Götze** (Frankfurt)

France: **Stephane Bonnet** (Paris)

- Time: **5:00 – 7:00 pm Beijing time** (9:00 – 11:00 am GMT)
- Zoom technology applied
- Zones in a comfortable time to connect to the meeting:  
**Africa – South America – North America – Asia – Australia – Europe**

2 cases will be discussed

## GIST OF THE 1<sup>ST</sup> CASE

- **A locally advanced esophageal middle thoracic squamous cell carcinoma with metastatic lymph nodes in the right recurrent nerve area.**
- **cT3N1M0 Stage III AJCC.**
- **4 cycles of neoadjuvant immunotherapy combined with chemotherapy applied. No adverse events.**
- **Minimally invasive McKeown esophagectomy with two-field lymphadenectomy 4 weeks after neoadjuvant therapy.**
- **Final pathological diagnosis: ypT0N0M0**

Discussion points, with the panel of experts:

- Value of additional PD-1 blockade
- Neoadjuvant therapy
- Combined immunotherapy
- Evaluation of clinical response to treatment
- Indications for surgery in patients with clinically complete response

## GIST OF THE 2<sup>ND</sup> CASE

- **A potentially resectable locally advanced middle thoracic squamous cell carcinoma**
- **cT3N1M0 Stage III AJCC.**
- **Neoadjuvant chemoradiotherapy (2 cycles + 40 Gy).**
  - **Poor response with tumor progression.**
- **Sequential chemotherapy combined with immunotherapy**
  - **Significant response**
- **Minimally invasive esophagectomy 4 weeks after, with radical tumor resection.**
- **Final pathological diagnosis: ypT1bN0M0**
- **Sudden death of unknown cause.**

Discussion points, with the panel of experts:

- Neoadjuvant therapy for locally advanced tumors
- Strategy for patients with poor response to chemoradiotherapy
- Indications for combined immunotherapy
- Indications for surgery in such patients
- Preferable surgical techniques after complex neoadjuvant therapy

Registration is free, but mandatory.

Free registration

*Eleven Pilot Centers worldwide are currently listed in the network of the OESO-SEMPIRE Platform of Excellence in Esophagology to take part in the program of the **OESO Virtual Educational Channel** in Esophagology. Such a program is in line with true multi-disciplinarity, the essence of OESO since its creation, and the mission defined by UNESCO in the **Chair of Digital Education** attributed in 2018, at the University of Geneva, to the OESO Foundation.*



The first three "Staff meeting discussions" were organized on May 28 (Pilot Center of Milan), July 22 (Pilot Center of Stanford) and October 3 (Pilot Center of Bomet, Kenya).

- ***Wherever you are in the world,***
- ***Whatever your specialty,***
- ***Whatever your level,***

the 4<sup>th</sup> clinical case of the OESO-SEMPIRE Platform will afford you the opportunity to participate in a global multidisciplinary staff meeting dedicated to 2 challenging cases of esophagology.

They will involve specialists from China as well from other parts of the world. Participants from any country can connect to the discussions.

Looking forward to seeing you soon!

**Robert Giuli, MD, FACS**

Professor of Surgery

Founder & Deputy Executive Director of OESO

The clinical cases coming up for discussion will be proposed by the Pilot Centers of

- **Geneva** (Switzerland) – December 2020
- **Melbourne** (Australia) – January 2021
- **Bordeaux** (France) – February 2021

*Details and time of these discussions will be announced on the OESO website and in future Newsletters.*

OESO Head Office  
2, Bd Pershing  
75017 Paris, France  
Tel. + 33 (0)1 55 37 90 15  
email: [michele.liegeon@oeso.org](mailto:michele.liegeon@oeso.org)  
[www.oeso.org](http://www.oeso.org)



OESO will not supply your Personal Data to any third party for marketing purposes, whether directly or indirectly.